
    
      A repeat-dose, open-label, 2-session study to assess the systemic exposure to, and
      pharmacodynamics of, fluticasone propionate HFA inhalation aerosol 88mcg administered
      twice-daily for 28 days delivered via an MDI and valved holding chamber with infant facemask
      to subjects ages 6 months to <12 months who have experienced 2 or more wheezing episodes in
      the preceding 6 months
    
  